Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 5, 2025, the Compensation ...

Puma Biotechnology release its 1Q'25 earnings results on May 8 after markets closed and followed with a conference call to ...

The PUMA Inhale sneaker belongs to the Cellerator family, which features the brand’s signature CELL cushioning technology.

Puma's cash runway may extend several years ... A Phase 1/2 trial evaluating NERLYNX for the treatment of HER2-mutant non-small cell lung cancer. A Phase 2 study evaluating NERLYNX for the ...

Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical ...